BR112015022473A2 - método e sistema para prever a resposta a tratamentos contra a dor - Google Patents

método e sistema para prever a resposta a tratamentos contra a dor

Info

Publication number
BR112015022473A2
BR112015022473A2 BR112015022473A BR112015022473A BR112015022473A2 BR 112015022473 A2 BR112015022473 A2 BR 112015022473A2 BR 112015022473 A BR112015022473 A BR 112015022473A BR 112015022473 A BR112015022473 A BR 112015022473A BR 112015022473 A2 BR112015022473 A2 BR 112015022473A2
Authority
BR
Brazil
Prior art keywords
response
individual
pain
predicting
drug
Prior art date
Application number
BR112015022473A
Other languages
English (en)
Inventor
Del Tredici Andria
ZHU Guangdan
David Becker K
Kuo-Fu Chan Russell
Moreno Tanya
Original Assignee
Pathway Genomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathway Genomics Corp filed Critical Pathway Genomics Corp
Publication of BR112015022473A2 publication Critical patent/BR112015022473A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

“método e sistema para prever a resposta a tratamentos contra a dor” resumo a presente invenção refere-se a sistemas e métodos para prever a resposta provável de um indivíduo de uma medicação para a dor compreendendo a genotipagem de variações genéticas em que um indivíduo para determinar a propensão do indivíduo pela metabolização de uma medicação para a dor e a resposta provável a um medicamento, e de preferência diversas reacções a um medicamento. em particular, o invento compreende a análise de uma amostra biológica é fornecida por uma pessoa, tipicamente um paciente ou de um indivíduo diagnosticado com um distúrbio particular, a determinação da resposta provável do indivíduo a um determinado tratamento, mais especificamente uma medicação para a dor, e em seguida visualizadas, ou ainda mais, recomendando um plano de ação ou inação. em particular, a presente invenção proporciona um método de classificação e sistema de perfil de resposta de um indivíduo com uma ou mais medicação para a dor. 1/1
BR112015022473A 2013-03-15 2014-03-12 método e sistema para prever a resposta a tratamentos contra a dor BR112015022473A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361800506P 2013-03-15 2013-03-15
US201361800560P 2013-03-15 2013-03-15
US13/917,509 US20140274763A1 (en) 2013-03-15 2013-06-13 Method and system to predict response to pain treatments
PCT/US2014/024939 WO2014151081A1 (en) 2013-03-15 2014-03-12 Method and system to predict response to pain treatments

Publications (1)

Publication Number Publication Date
BR112015022473A2 true BR112015022473A2 (pt) 2017-07-18

Family

ID=51529821

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022473A BR112015022473A2 (pt) 2013-03-15 2014-03-12 método e sistema para prever a resposta a tratamentos contra a dor

Country Status (5)

Country Link
US (3) US20140274763A1 (pt)
EP (1) EP2973131A4 (pt)
BR (1) BR112015022473A2 (pt)
HK (1) HK1220520A1 (pt)
WO (1) WO2014151081A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140244556A1 (en) * 2013-02-27 2014-08-28 Abdul Saleh Methods for and apparatus generating automated pharmaco genetics correlation
US20160224754A1 (en) * 2015-01-30 2016-08-04 Elly Hann Systems and methods for an interactive assessment and display of drug toxicity risks
US20190055603A1 (en) * 2015-04-28 2019-02-21 Proove Biosciences, Inc. System and method for processing genotype information relating to drug metabolism
CN107273710A (zh) * 2017-08-22 2017-10-20 北京岙特杰诺生物科技有限公司 一种建立药物代谢酶基因与药物代谢的关系模型的方法
CN107893114A (zh) * 2017-12-29 2018-04-10 韩林志 用于指导芬太尼类药物个体化用药相关基因检测的引物对、试剂盒及方法
JP6893052B1 (ja) * 2020-06-29 2021-06-23 ゲノム・ファーマケア株式会社 投与計画提案システム、方法およびプログラム
CN112553325A (zh) * 2020-12-29 2021-03-26 广东南芯医疗科技有限公司 舒芬太尼个体化用药基因的指导方法及试剂盒
US20220389509A1 (en) * 2021-05-25 2022-12-08 Raymond F. Anton Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in individuals diagnosed with alcohol use disorder
CN113584161A (zh) * 2021-06-15 2021-11-02 湖南菲思特精准医疗科技有限公司 一种芬太尼代谢标志物的检测试剂盒及其检测方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002302223A1 (en) * 2001-05-07 2002-11-18 Mcgill University Individualization of therapy with analgesics
WO2003008637A2 (en) * 2001-07-17 2003-01-30 Xanthus Life Sciences, Inc. Use of genotyping in the individualization of therapy
WO2005038049A2 (en) * 2003-10-06 2005-04-28 Heinrich Guenther System and method for optimizing drug therapy
CA2594730A1 (en) * 2005-01-13 2006-07-20 Progenika Biopharma, S.A. Methods and products for in vitro genotyping
DK2508621T3 (en) * 2005-11-29 2015-01-12 Childrens Hosp Medical Center Optimization and individualization of drug selection and dosage
GB0614396D0 (en) * 2006-07-20 2006-08-30 Knox Geoffrey M Test for the presence of active CYP450 2D6
EP2102651A4 (en) * 2006-11-30 2010-11-17 Navigenics Inc GENERALYSIS SYSTEMS AND METHODS
CN101376908B (zh) * 2007-08-29 2012-01-25 中国科学院大连化学物理研究所 一种基于分子和细胞水平研究药物代谢的方法
WO2009095877A2 (en) * 2008-01-31 2009-08-06 Fund For Medical Research Development Of Infrastructure And Health Services Rambam Medical Center Method of predicting pain medication efficacy
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
US9558320B2 (en) * 2009-10-26 2017-01-31 Genomas, Inc. Physiogenomic method for predicting drug metabolism reserve for antidepressants and stimulants
US9944985B2 (en) * 2011-11-30 2018-04-17 Children's Hospital Medical Center Personalized pain management and anesthesia: preemptive risk identification and therapeutic decision support

Also Published As

Publication number Publication date
WO2014151081A1 (en) 2014-09-25
US20170051349A1 (en) 2017-02-23
EP2973131A1 (en) 2016-01-20
US20140274763A1 (en) 2014-09-18
US20170247760A1 (en) 2017-08-31
HK1220520A1 (zh) 2017-05-05
EP2973131A4 (en) 2017-03-15

Similar Documents

Publication Publication Date Title
BR112015022473A2 (pt) método e sistema para prever a resposta a tratamentos contra a dor
Magnavita et al. Sleep, health and wellness at work: a scoping review
National Collaborating Centre for Mental Health (UK Self-harm: longer-term management
BR112015022472A2 (pt) método e sistema para prever a resposta a tratamentos para transtornos mentais
Hobbs et al. Integrating iCBT for generalized anxiety disorder into routine clinical care: treatment effects across the adult lifespan
BR112017006219A2 (pt) sistema de controle para controle de distribuição de medicamentos
Miller et al. The immunology of behavior—Exploring the role of the immune system in brain health and illness
BR112012020101A2 (pt) método diagnósticos e terapêuticos usando anticorpos anti-cd200.
BR112014018433A8 (pt) Métodos para determinar o período circadiano em um indivíduo humano e um tau de um paciente, para tratar um paciente humano, para fornecer informação relativa a um ritmo circadiano do paciente, e para converter dados da concentração de melatonina ou substituto de melantonina nos dados do ritmo circadiano, sistema, e, meio de armazenagem legível por computador
AU2018272076A1 (en) Products and methods for therapeutic administration of microorganisms to non-human animals
Pawar Level of stress among the nurses working in Intensive care units
WO2012145499A3 (en) System and method for medical messaging
Garg et al. Exacerbation of auditory verbal hallucinations with adjunctive high-frequency cerebellar vermal repetitive transcranial magnetic stimulation in schizophrenia: a case report
UA78641U (ru) Способ прогнозирования тяжести больных острым панкреатитом
BR112015024516A2 (pt) métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação
ÇALIŞKAN et al. ILLNESS PERCEPTION OF THE PATIENTS WITH HEMATOLOGICAL CANCERS: A SINGLE CENTER STUDY
Machfudz Quality of life epilepsy in childhood: Comparison between well-controlled epilepsy and non epilepsy
Oniz et al. An examination of behavioral odor data in sensory disabled individuals
Poodineh et al. Investigating the Effect of Muscular Relaxation Technique on Sleep Quality in Children with Leukemia Treated with Chemotherapy in Educational Hospitals of Zahedan
Titov et al. Improving Adherence and Clinical Outcomes in Self-Guided Internet Treatment for
Fingelkurts et al. Turning Back the Clock: A Retrospective Single-Blind Study on Brain Age Change in Response to Nutraceuticals Supplementation vs. Lifestyle Modifications
De Taeye et al. Preserved attention allocation but impaired emotion regulation in epilepsy with comorbid negative affect: electrophysiological time course
Reddy et al. Neuropsychological assessment and intervention for emotion-and behavior-disordered youth: Opportunities for practice.
Muir-Cochrane Hospitality in mental health nursing
Kubesch et al. Association of cathechol O-methyltransferaser (COMT) polymorphism and executive function in adolescents

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired